Home » EFCG Calls for Mandatory Inspections of API Manufacturing Sites
EFCG Calls for Mandatory Inspections of API Manufacturing Sites
European Fine Chemicals Group
The European Fine Chemicals Group (EFCG) is proposing a global harmonization of the rules and regulations governing the manufacture of active pharmaceutical ingredients (APIs) to level the worldwide playing field to ensure the quality of APIs and medicines containing them meet the high standard recognised by the developed economies (ICH Q7).
This should be achieved via mandatory inspections of all global API manufacturers via a Mutual Recognition Agreement (MRA) approach and managed by the National Regulatory authorities to share scarce inspection resources and to avoid the present duplication.
This message is at the core of the latest EFCG position paper aimed at all stakeholders in the global API supply chain, including the Regulators, previewed during their October press conference at the CPhI exhibition in Madrid and repeated in their recent joint response (with APIC and SOCMA) to the EU-US Public Consultation on the future of EU-US trade and economic relations, which provides proposals for the EU-US High Level Working Group on
Jobs and Growth and to the EU-US High Level Regulatory Cooperation Forum.
EFCG believes that the new Falsified Medicines Directive (2011/62/EU) designed to minimize counterfeit medicines entering the EU market does not adequately address the API quality issues and that in reality it does little to improve upon the present Directive (2001/83/EC) with regard to patient safety.
Evidence of illegal API manufacturing activity in Asia since 2003 is given in the paper, including the 2008 Chinese-sourced heparin case in the USA that caused >100 deaths due to a deliberately included and undeclared impurity.
Syrian Pharma Production Nearly Halted by WarFrom AFP
A shortage of foreign currency has brought production to a near halt in Syria
Camfil APC Opens Manufacturing Plant in the UKFrom Camfil
Camfil announced the grand opening of its new 40,000-sq.-ft. facility
Actavis Acquiring Warner Chilcott for $8.5BFrom AP
Actavis to buy Warner Chilcott in an all-stock transaction
Northwest Analytics Launches Next Generation Enterprise Manufacturing Intelligence SolutionFrom Northwest Analytics
NWA Focus EMI Delivers Real Time Process Intelligence and Unique Accelerating Modules - a Shared Knowledge Base and Manufacturing-Centric Collaboration
Innovative Clinical Development Partnership Announced By Quintiles and Merck SeronoFrom MarketWatch.com
Agreement creates unique strategic collaboration for development and clinical trial execution
$15 Billion Myland Offer Rejected By ActavisFrom Bloomberg.com
Actavis has rejected drugmaker Mylan Inc's cash-and-stock offer for $15 billion. They have decided to continue talks to take over Warner Chilcott Plc instead, sources have said.
Rapid Micro Biosystems Offers Workshops at New European Headquarters in MunichFrom Rapid Micro Biosystems
Company hosts hands-on demonstrations of its Growth Direct System
Amgen, Zhejiang Beta Pharma Form Joint VentureFrom FOX Business
Amgen will form a joint venture with Chinese pharma firm to bring its colon cancer drug Vectibix to the Chinese market
Academic Tech Transfer Collaboration Required for Pharma R&D ModelFrom IT News Online
Pharma R&D Model Needs Academic Tech Transfer Collaboration for the Future of Drug Innovation Says New Report
CEM Wins Solid-Phase Peptide Synthesis Patent DisputeFrom CEM
CEM's European Patent covering microwave assisted solid phase peptide synthesis has been upheld in an oral proceeding
- All news »